Efficacy and Safety of Single Oral Dosing of Secnidazole for Trichomoniasis in Women: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Delayed-Treatment Study

Christina A Muzny, Jane R Schwebke, Paul Nyirjesy, Gregory Kaufman, Leandro A Mena, Gweneth B Lazenby, Olivia T Van Gerwen, Keonte J Graves, Janeen Arbuckle, Belvia A Carter, Connette P McMahon, Scott Eder, Jackie Shaw, Brajesh Pandey, Steven E Chavoustie, Christina A Muzny, Jane R Schwebke, Paul Nyirjesy, Gregory Kaufman, Leandro A Mena, Gweneth B Lazenby, Olivia T Van Gerwen, Keonte J Graves, Janeen Arbuckle, Belvia A Carter, Connette P McMahon, Scott Eder, Jackie Shaw, Brajesh Pandey, Steven E Chavoustie

Abstract

Background: Trichomonas vaginalis is the most prevalent nonviral sexually transmitted infection. We evaluated the efficacy and safety of secnidazole vs placebo in women with trichomoniasis.

Methods: Women with trichomoniasis, confirmed by a positive T. vaginalis culture, were randomized to single-dose oral secnidazole 2 g or placebo. The primary endpoint was microbiological test of cure (TOC) by culture 6-12 days after dosing. At the TOC visit, participants were given the opposite treatment. They were followed for resolution of infection afterward and offered treatment at subsequent visits, if needed. Fifty patients per group (N = 100) provided approximately 95% power to detect a statistically significant difference between treatment groups.

Results: Between April 2019 and March 2020, 147 women enrolled at 10 sites in the United States. The modified intention-to-treat (mITT) population included 131 randomized patients (secnidazole, n = 64; placebo, n = 67). Cure rates were significantly higher in the secnidazole vs placebo group for the mITT population (92.2% [95% confidence interval {CI}: 82.7%-97.4%] vs 1.5% [95% CI: .0%-8.0%]) and for the per-protocol population (94.9% [95% CI: 85.9%-98.9%] vs 1.7% [95% CI: .0%-8.9%]). Cure rates were 100% (4/4) in women with human immunodeficiency virus (HIV) and 95.2% (20/21) in women with bacterial vaginosis (BV). Secnidazole was generally well tolerated. The most frequently reported treatment-emergent adverse events (TEAEs) were vulvovaginal candidiasis and nausea (each 2.7%). No serious TEAEs were observed.

Conclusions: A single oral 2 g dose of secnidazole was associated with significantly higher microbiological cure rates vs placebo, supporting a role for secnidazole in treating women with trichomoniasis, including those with HIV and/or BV.

Clinical trials registration: NCT03935217.

Keywords: Trichomonas vaginalis; secnidazole; trichomoniasis; women.

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Modified intention-to-treat population and reasons for exclusion. aPatients could have multiple reasons for exclusion. bChlamydia trachomatis/Neisseria gonorrhoeae by nucleic acid amplification test. Abbreviations: BL, baseline; mITT, modified intention-to-treat; STI, sexually transmitted infection; TV, Trichomonas vaginalis.
Figure 2.
Figure 2.
Per-protocol population and reasons for exclusion. aChlamydia trachomatis/Neisseria gonorrhoeae by nucleic acid amplification test. bPatient did not abstain from sexual intercourse during the study. cPatients could have multiple reasons for exclusion. Abbreviations: BL, baseline; PP, per protocol; STI, sexually transmitted infection; TOC, test of cure; TV, Trichomonas vaginalis.

References

    1. Flagg EW, Meites E, Phillips C, Papp J, Torrone EA. Prevalence of trichomonas vaginalis among civilian, noninstitutionalized male and female population aged 14 to 59 years: United States, 2013 to 2016. Sex Transm Dis 2019; 46:e93–6.
    1. McClelland RS, Sangare L, Hassan WM, et al. . Infection with trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis 2007; 195:698–702.
    1. Committee on Practice Bulletins-Gynecology. Vaginitis in nonpregnant patients: ACOG practice bulletin, number 215. Obstet Gynecol 2020; 135:e1–17.
    1. Mielczarek E, Blaszkowska J. Trichomonas vaginalis: pathogenicity and potential role in human reproductive failure. Infection 2016; 44:447–58.
    1. Silver BJ, Guy RJ, Kaldor JM, Jamil MS, Rumbold AR. Trichomonas vaginalis as a cause of perinatal morbidity: a systematic review and meta-analysis. Sex Transm Dis 2014; 41:369–76.
    1. Workowski KA, Bolan GA; Centers for Disease Control and Prevention . Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1–137.
    1. Kissinger P, Muzny CA, Mena LA, et al. . Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial. Lancet Infect Dis 2018; 18:1251–9.
    1. Nyirjesy P, Schwebke JR. Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment. Future Microbiol 2018; 13:507–24.
    1. Bohbot JM, Vicaut E, Fagnen D, Brauman M. Treatment of bacterial vaginosis: a multicenter, double-blind, double-dummy, randomised phase III study comparing secnidazole and metronidazole. Infect Dis Obstet Gynecol 2010; 2010:705692.
    1. Schwebke JR, Morgan FG Jr, Koltun W, Nyirjesy P. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. Am J Obstet Gynecol 2017; 217:678.e1–9.
    1. Gillis JC, Wiseman LR. Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis. Drugs 1996; 51:621–38.
    1. US Food and Drug Administration. Uncomplicated urinary tract infections: developing drugs for treatment guidance for industry. Rockville, MD: FDA, 2019.
    1. Pentikis HS, Adetoro N, Kaufman G. In vitro metabolic profile and drug-drug interaction assessment of secnidazole, a high-dose 5-nitroimidazole antibiotic for the treatment of bacterial vaginosis. Pharmacol Res Perspect 2020; 8:e00634.
    1. Lupin Pharmaceuticals Inc. Solosec (secnidazole) [package insert]. Baltimore, MD: Lupin Pharmaceutical Inc, 2017.
    1. US Food and Drug Administration. Bacterial vaginosis: developing drugs for treatment guidance for industry. Report No.: FDA-2016-D-1659. Rockville, MD: FDA, 2019.
    1. Rivers CA, Muzny CA, Schwebke JR. Diagnostic rates differ on the basis of the number of read days with the use of the InPouch culture system for Trichomonas vaginalis screening. J Clin Microbiol 2013; 51:3875–6.
    1. Beverly AL, Venglarik M, Cotton B, Schwebke JR. Viability of Trichomonas vaginalis in transport medium. J Clin Microbiol 1999; 37:3749–50.
    1. Ohlemeyer CL, Hornberger LL, Lynch DA, Swierkosz EM. Diagnosis of Trichomonas vaginalis in adolescent females: InPouch TV culture versus wet-mount microscopy. J Adolesc Health 1998; 22:205–8.
    1. Craig-Kuhn MC, Granade C, Muzny CA, et al. . Optimal timing for trichomonas vaginalis test of cure using nucleic acid amplification testing. Sex Transm Dis 2019; 46:312–6.
    1. Klebanoff MA, Carey JC, Hauth JC, et al. ; National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units . Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001; 345:487–93.
    1. Sutton M, Sternberg M, Koumans EH, McQuillan G, Berman S, Markowitz L. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001–2004. Clin Infect Dis 2007; 45:1319–26.
    1. Kissinger P, Mena L, Levison J, et al. . A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women. J Acquir Immune Defic Syndr 2010; 55:565–71.
    1. Pentikis HS, Adetoro N. Two phase 1, open-label, single-dose, randomized, crossover studies to assess the pharmacokinetics, safety, and tolerability of orally administered granules of secnidazole (2 g) in healthy female volunteers under different administration conditions. Clin Pharmacol Drug Dev 2018; 7:543–53.
    1. Muzny CA, Kardas P. A narrative review of current challenges in the diagnosis and management of bacterial vaginosis. Sex Transm Dis 2020; 47:441–6.
    1. Bartley JB, Ferris DG, Allmond LM, Dickman ED, Dias JK, Lambert J. Personal digital assistants used to document compliance of bacterial vaginosis treatment. Sex Transm Dis 2004; 31:488–91.
    1. Cotch MF, Pastorek JG 2nd, Nugent RP, et al. . Trichomonas vaginalis associated with low birth weight and preterm delivery. The Vaginal Infections and Prematurity Study Group. Sex Transm Dis 1997; 24:353–60.
    1. Minkoff H, Grunebaum AN, Schwarz RH, et al. . Risk factors for prematurity and premature rupture of membranes: a prospective study of the vaginal flora in pregnancy. Am J Obstet Gynecol 1984; 150:965–72.
    1. Moodley P, Connolly C, Sturm AW. Interrelationships among human immunodeficiency virus type 1 infection, bacterial vaginosis, trichomoniasis, and the presence of yeasts. J Infect Dis 2002; 185:69–73.
    1. Sobel JD, Subramanian C, Foxman B, Fairfax M, Gygax SE. Mixed vaginitis-more than coinfection and with therapeutic implications. Curr Infect Dis Rep 2013; 15:104–8.
    1. Siboulet A, Catalan F, Videau D, Niel G. La trichomonase urogénitale. Essais d’un imidazole à demi-vie longue: le secnidazole. Méd Mal Infect 1977; 7:400–4.
    1. Videau D, Niel G, Siboulet A, Catalan F. Secnidazole. A 5-nitroimidazole derivative with a long half-life. Br J Vener Dis 1978; 54:77–80.
    1. Pentikis H, Eder S, Kaufman G, Chavoustie S. Secnidazole, an approved single dose drug for bacterial vaginosis, does not cause reproductive toxicity in animals. In: American Academy of Obstetricians and Gynecologists, Seattle, Washington, 2020.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel